NeuroRx's NRX-101 improves depression and suicidality in Phase II

NeuroRx Inc. (Wilmington, Del.) said NRX-101 improved depression and suicidality in the Phase II STABIL-B trial to treat severe bipolar depression and acute suicidal ideation and behavior. Data were presented in

Read the full 311 word article

How to gain access

Continue reading with a
two-week free trial.